NEWPORT BEACH, Calif.–(BUSINESS WIRE)–Renata Medical, a leader in innovative vascular solutions for young, growing patients, proudly announces a major milestone with the successful implantation of its Minima Growth Stent in the first patient following its recent FDA approval. “Today marks the beginning of something special” Post this “Today marks the […]
Coronary/Structural Heart
ESC Congress 2024: INFINITY-SWEDEHEART Trial of Elixir Medical’s DynamX Bioadaptor Meets Primary Endpoint and Clinical Results Confirm Unique Mechanism of Action
—Largest randomized data set to date on bioadaptor, with a complex patient population of 2,400 compared to a DES— —Primary endpoint of target lesion failure (TLF) non-inferiority at twelve months was met with a low event rate for DynamX despite increased patient complexity— —Pre-specified landmark analysis shows statistically significant reduction […]
ADLM publishes new guidance on lipid testing to improve care for patients with cardiovascular disease
WASHINGTON, Sept. 3, 2024 /PRNewswire/ — The Association for Diagnostics & Laboratory Medicine (ADLM, formerly AACC) has issued expert guidance on lipid tests, which measure blood levels of fats and cholesterol to help assess a patient’s risk of heart disease and stroke. By giving…
Caristo Diagnostics Recognized as Quarterfinalist in the Digital Health Awards, Rising Star Category
OXFORD, England, Sept. 3, 2024 /PRNewswire/ — Caristo Diagnostics, a global leader in cardiovascular disease diagnostics and risk prediction, has been selected as a quarterfinalist for the prestigious Digital Health Hub Foundation: Digital Health Awards. Caristo was chosen as a…
Vasa Therapeutics Announces Initiation of Phase 1 First-in-Human Clinical Trial of VS-041 for the Treatment of Heart Failure with Preserved Ejection Fraction
Vasa Therapeutics granted MHRA Clinical Trial Authorization (CTA) for VS-041 for the treatment of heart failure with preserved ejection fraction (HFpEF) Company’s seed funding extended to $11M ENCINITAS, Calif. and WROCLAW, Poland, Sept. 3, 2024 /PRNewswire/ — Vasa Therapeutics (“Vasa”),…
Recor Medical Endorses European Society of Cardiology’s New Guidelines for Management of Hypertension
The new ESC Guidelines for Management of Elevated Blood Pressure and Hypertension were presented at the ESC Congress in London and reinforce the safety and effectiveness of renal denervation, recommending its consideration as a treatment option to improve uncontrolled hypertension. PALO…
Cytokinetics Presents Additional Data From SEQUOIA-HCM at the European Society of Cardiology Congress 2024
Additional Data from SEQUOIA-HCM Demonstrate Favorable Cardiac Remodelingby Cardiac MRI, Improvements in Cardiac Structure and Function by Echocardiography,Symptom Relief and Improvement in Biomarkers with Aficamten
ESC Congress 2024: Bayer to Present Phase III KERENDIA® (finerenone) Data
Hot Line Sessions to Feature Results from Investigational FINEARTS-HF Study in Heart Failure with Mildly Reduced or Preserved Ejection Fraction and Pooled, Exploratory Analysis from Three Pivotal Phase III Trials Exploring Finerenone on Cardio-Kidney Outcomes Detailed data from the Phase III FINEARTS-HF trial that investigated KERENDIA® (finerenone) in patients with heart […]
Renata Medical Receives FDA Approval for the Minima Growth Stent, First-of-its-Kind Device for Treating Aortic Coarctation and Pulmonary Artery Stenosis
August 29, 2024 08:21 AM Eastern Daylight Time NEWPORT BEACH, Calif.–(BUSINESS WIRE)–Renata Medical today announced that the U.S. Food and Drug Administration (FDA) has approved the company’s first-of-its-kind Minima Growth Stent that’s specifically tailored for neonates, infants, and young children, but also designed to be re-expanded over the course of their […]
BridgeBio to Present Additional Analyses from the Phase 3 ATTRibute-CM Trial of Acoramidis in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at the ESC Congress 2024 and the HFSA Annual Meeting 2024
PALO ALTO, Calif., Aug. 29, 2024 (GLOBE NEWSWIRE) — BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases, announced today that additional data on clinical outcomes from ATTRibute-CM, its Phase 3 study of acoramidis in ATTR-CM, will be presented at the European Society of Cardiology (ESC) Congress 2024, taking place in London, United Kingdom on August 30 – September 2, 2024 and the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2024, taking place in Atlanta, Georgia on September 27 – 30, 2024.



